The Patent Trial and Appeal Board (PTAB) has partly accepted pharmaceutical company Lupin Limited’s petition for an inter partes review (IPR) of claims in a patent covering a compound that helps to treat HIV.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Vertex Pharmaceuticals; Lupin Limited; PTAB; HIV; inter partes review; patents; USPTO; Patent Trial and Appeal Board